Back to Journals » Drug Design, Development and Therapy » Volume 7

Canagliflozin: a novel treatment option for type 2 diabetes

Authors Dietrich E, Powell J, Taylor J

Received 16 July 2013

Accepted for publication 12 September 2013

Published 22 November 2013 Volume 2013:7 Pages 1399—1408


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Eric Dietrich,1 Jason Powell,2 James R Taylor2

1University of Florida College of Medicine, Department of Community Health and Family Medicine, 2University of Florida College of Pharmacy, Department of Pharmacotherapy and Translational Research, Gainesville, FL, USA

Abstract: Type 2 diabetes continues to be a challenging disease to manage. The addition of new agents with a positive risk–benefit ratio could potentially assist clinicians and patients in achieving adequate diabetes control. Canagliflozin, the first sodium-glucose cotransporter 2 inhibitor presently available on the market, offers a unique mechanism of action: it inhibits renal reabsorption of glucose, thereby increasing urinary glucose excretion. It reduces hemoglobin A1c by approximately 0.37%–1.16%; it also reduces the patient's weight and systolic blood pressure and has a low risk for hypoglycemia. Adverse effects include an increased risk of urinary tract infections and genital mycotic infections. In this manuscript we review canagliflozin and its potential role in management of type 2 diabetes mellitus.

Keywords: canagliflozin, SGLT2 inhibitor, type 2 diabetes, oral hypoglycemic

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]